title: Cost and outcome in stem cell collections in HLA-haplo identical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies.
abstract: Unmanipulated HLA-haplo identical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized peripheral blood stem cells (G-PBSCs) and granulocyte-colony stimulating factor-mobilized bone marrow (G-BM) has been developed as an alternative transplantation strategy for patients without an HLA-matched related or unrelated donor. In this transplantation setting, the cost and outcome of stem cell collections have not been defined completely. The aim of this study was to compare the cost and outcome of stem cell collection in HLA-haplo identical/mismatched related transplantation with combined G-PBSCs and G-BM to the HLA-identical/matched transplantation with G-PBSCs alone for patients with hematologic malignancies. Hundred and fifty-two healthy donors received twice-daily granulocyte-colony stimulating factor (G-CSF) subcutaneously for 5 days. The PBSCs were collected on day 4 and 5 of G-CSF treatment for HLA-identical/matched transplantation from unrelated/related donors. The PBSC collections and BM harvests was performed on day 4 and 5 of G-CSF treatment for HLA-haplo identical/mismatched related transplantation from related donors, respectively. There was no difference in the major characteristics between groups. More stem cells were harvested in HLA-haplo identical/mismatched related donors than that of HLA-identical/matched donors and a lower cost was seen in the former. The HLA-haplo identical/mismatched related transplantation with combined G-PBSCs and G-BM was a feasible approach with high cell harvest and low cost of stem cell collection for patients with hematologic malignancies.
authors.affiliation: Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, People's Republic of China. xhchen888@yahoo.com.cn
authors.forename: Xing-Hua
authors.initials: XH
authors.lastname: Chen
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhang
authors.forename: Xi
authors.initials: X
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Gao
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
authors.forename: Pei-Yan
authors.initials: PY
authors.lastname: Kong
authors.forename: Xian-Gui
authors.initials: XG
authors.lastname: Peng
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Sun
authors.forename: Dong-Feng
authors.initials: DF
authors.lastname: Zeng
authors.forename: Qing-Yu
authors.initials: QY
authors.lastname: Wang
mesh_terms: D000328:Adult; D001782:Blood Donors; D016026:Bone Marrow Transplantation / Q000191:economics*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006680:HLA Antigens / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male; D033581:Stem Cell Transplantation / Q000191:economics* / Q000379:methods; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens; D016179:Granulocyte Colony-Stimulating Factor